# Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

> **NCT05882630** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Surufatinib,Serplulimab,Etoposide,Carboplatin

## Key facts

- **NCT ID:** NCT05882630
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05882630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05882630, "Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05882630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*